Does Blue Cross Blue Shield of Alabama Cover Semaglutide (Wegovy)?
HealthRX.com
BCBS Alabama coverage depends on the specific plan
Key numbers
- 86.4%Share of STEP 1 adults on semaglutide who reached at least 5% weight loss, versus 31.5% on placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 31.5%Share of STEP 1 adults on placebo who reached at least 5% weight lossSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 50.5%Share of STEP 1 adults on semaglutide who reached at least 15% weight lossSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 4.9%Share of STEP 1 adults on placebo who reached at least 15% weight lossSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Semaglutide
At a glance
- What Wegovy treats / Weight reduction and CV risk reduction (injection and tablet); MASH (injection only) [1]
- Forms / Weekly injection and a once-daily 25 mg tablet for adults [1]
- Approval dates / Wegovy injection 2021-06-04; Wegovy tablets 2025-12-22 [2][3]
- Prescription status / Prescription-only; none sold over the counter [1]
- Ozempic / A separate approval for type 2 diabetes, with no weight-loss indication [1][4]
- Compounded semaglutide / Not FDA approved and not reviewed for safety, effectiveness or quality [5]
What the Wegovy label covers
The Wegovy injection label lists three uses, each alongside a reduced-calorie diet and increased physical activity: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; reducing excess body weight and maintaining the loss in adults and children aged 12 and older with obesity, and in adults with overweight plus at least one weight-related condition; and treating noncirrhotic MASH with moderate to advanced fibrosis (stages F2 to F3) in adults, under accelerated approval [1].
Wegovy comes as a weekly injection and a once-daily 25 mg tablet. The injection was approved on 2021-06-04 [2]. The tablet was approved on 2025-12-22 and is for adults only: it is indicated for weight reduction and cardiovascular risk reduction, and the label gives it no pediatric or MASH indication [1][3].
The label also carries a limitation of use: taking Wegovy with another semaglutide-containing product or with any other GLP-1 receptor agonist is not recommended [1].
Questions worth asking
Ozempic is a different approval
Ozempic contains semaglutide too, but it is approved for type 2 diabetes (NDA 209637, original approval 2017-12-05) and has no weight-loss indication [1][4]. Wegovy sits under NDA 215256 [2].
What people on Reddit report
Reddit accounts from people trying to get Wegovy approved under a Blue Cross Blue Shield plan, including one with a BCBS Alabama plan through an employer. They describe the formulary and approval rules they ran into.
Has anyone had any luck getting Wegovey under BCBS of Alabama? I live in PA but our insurance is BCBS of Alabama and it doesn't look like we can get it with an RX and a PA.Read the source discussion
Thank you. Unfortunately, I think i'm out of luck. I wish insurance would catch on and start covering these drugs. We have the most comprehensive plan offered by my husbands employer and it's only covering Ozempic if you are diabetic.Read the source discussion
It's listed as a 4+ tier designation. Ozempic is 3 with step therapy and to your point you need to be diabetic.Read the source discussion
Look on your formulary list. It will say criteria. They won't over ozempic for non diabetics but will cover wegovy if your bmi is over 35 I think.Read the source discussion
The weight-loss results behind the indication
STEP 1 was a double-blind, 68-week trial of 1,961 adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, and no diabetes. Mean weight change was -14.9% with semaglutide 2.4 mg weekly versus -2.4% with placebo. At least 5% weight loss was reached by 86.4% on semaglutide and 31.5% on placebo; at least 15% by 50.5% and 4.9% [6].
Compounded semaglutide is not an approved product
FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are marketed [5]. FDA declared the semaglutide injection shortage resolved on 2025-02-21, and the enforcement discretion that had allowed shortage-based compounding ended in 2025 [7].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Does BCBS Alabama cover Wegovy?
What is Wegovy FDA approved to treat?
Is Ozempic coverage the same as Wegovy coverage?
Is the Wegovy pill covered the same way as the injection?
What weight loss did the Wegovy trials show?
Does BCBS Alabama cover compounded semaglutide?
References
Show all 8 referencesHide references
- U.S. National Library of Medicine, DailyMed. Wegovy injection and tablets prescribing information. Wegovy injection and tablets label
- Drugs@FDA: FDA-Approved Drugs.
- Drugs@FDA: FDA-Approved Drugs.
- Drugs@FDA: FDA-Approved Drugs.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA.
- Reddit participants. Wegovy Approval for BCBS AL? (r/WegovyWeightLoss). Accessed 2026-11-10.